{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T11:05:56Z","timestamp":1789988756405,"version":"4.0.1"},"reference-count":29,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,12,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The treatment landscape of chronic lymphocytic leukemia (CLL) has evolved considerably over the past decade due to the development of effective novel agents with varying mechanisms of action, including Bruton tyrosine kinase (BTK) and B-cell lymphoma 2 (BCL2) inhibitors. Extrapolating upon the success of anti-CD20\u2013directed chemoimmunotherapy, a dual-targeted approach has been explored in treatment-naive patients with CLL. Anti-CD20 monoclonal antibody combinations with BTK inhibitors as well as BCL2 inhibitors have demonstrated superiority over traditional cytotoxic chemoimmunotherapy regimens such as fludarabine, cyclophosphamide, and rituximab; bendamustine-rituximab; and obinutuzumab-chlorambucil. Impressive clinical benefit is seen in both younger and older patients, those with comorbidities, and, most importantly, those with poor prognostic features. Given this success, combinations of BTK inhibitors and venetoclax have been explored in clinical trials. These dual-targeted regimens provide remarkable efficacy while allowing for an all-oral approach and fixed duration of treatment. Current investigations under way are evaluating the utility of a triplet approach with the addition of obinutuzumab in comparison to a doublet approach.<\/jats:p>","DOI":"10.1182\/hematology.2023000506","type":"journal-article","created":{"date-parts":[[2023,12,8]],"date-time":"2023-12-08T15:11:25Z","timestamp":1702048285000},"page":"421-426","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":4,"title":["Dual-targeted regimens for the frontline treatment of CLL"],"prefix":"10.1182","volume":"2023","author":[{"given":"Chaitra","family":"Ujjani","sequence":"first","affiliation":[{"name":"Fred Hutchinson Cancer Center, University of Washington, Division of Medical Oncology, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2023,12,8]]},"reference":[{"issue":"2","key":"2023120815065654000_hem2023000506C1","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1182\/blood.2021014960","article-title":"Long-term outcomes for ibrutinib-rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial","volume":"140","author":"Shanafelt","year":"2022","journal-title":"Blood"},{"issue":"suppl 1","key":"2023120815065654000_hem2023000506C2","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1182\/blood-2021-152319","article-title":"Ibrutinib plus rituximab is superior to FCR in previously untreated CLL: results of the phase III NCRI FLAIR trial","volume":"138","author":"Hillmen","year":"2021","journal-title":"Blood"},{"issue":"suppl 1","key":"2023120815065654000_hem2023000506C3","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1182\/blood-2021-153146","article-title":"Long-term results of Alliance A041202 show continued advantage of ibrutinib-based regimens compared with bendamustine plus rituximab chemoimmunotherapy","volume":"138","author":"Woyach","year":"2021","journal-title":"Blood"},{"issue":"9","key":"2023120815065654000_hem2023000506C4","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.3324\/haematol.2021.279012","article-title":"First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMINATE trial","volume":"107","author":"Moreno","year":"2022","journal-title":"Haematologica"},{"issue":"16, suppl","key":"2023120815065654000_hem2023000506C5","doi-asserted-by":"crossref","first-page":"7539","DOI":"10.1200\/JCO.2022.40.16_suppl.7539","article-title":"Acalabrutinib\u200a\u00b1\u200aobinutuzumab versus obinutuzumab + chlorambucil in treatment-na\u00efve chronic lymphocytic leukemia: five-year follow-up of ELEVATE-TN","volume":"40","author":"Sharman","year":"2022","journal-title":"J Clin Oncol"},{"issue":"8","key":"2023120815065654000_hem2023000506C6","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1182\/blood.2021015014","article-title":"Enduring undetectable MRD and updated outcomes in relapsed\/refractory CLL after fixed-duration venetoclax-rituximab","volume":"140","author":"Seymour","year":"2022","journal-title":"Blood"},{"issue":"1","key":"2023120815065654000_hem2023000506C7","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1038\/s41467-023-37648-w","article-title":"Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia","volume":"14","author":"Al-Sawaf","year":"2023","journal-title":"Nat Commun"},{"issue":"19","key":"2023120815065654000_hem2023000506C8","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1056\/NEJMoa2213093","article-title":"First-line venetoclax combinations in chronic lymphocytic leukemia","volume":"388","author":"Eichhorst","year":"2023","journal-title":"N Engl J Med"},{"issue":"suppl 1","key":"2023120815065654000_hem2023000506C9","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1182\/blood-2022-170850","article-title":"Combined ibrutinib and venetoclax for first-line treatment of patients with chronic lymphocytic leukemia (CLL): 4-year follow-up data","volume":"140","author":"Jain","year":"2022","journal-title":"Blood"},{"issue":"34","key":"2023120815065654000_hem2023000506C10","doi-asserted-by":"crossref","first-page":"3853","DOI":"10.1200\/JCO.21.00807","article-title":"Ibrutinib plus venetoclax for first-line treatment of chronic lymphocytic leukemia: primary analysis results from the minimal residual disease cohort of the randomized phase II CAPTIVATE study","volume":"39","author":"Wierda","year":"2021","journal-title":"J Clin Oncol"},{"issue":"22","key":"2023120815065654000_hem2023000506C11","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.1182\/blood.2021014488","article-title":"Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort","volume":"139","author":"Tam","year":"2022","journal-title":"Blood"},{"issue":"suppl 16","key":"2023120815065654000_hem2023000506C12","doi-asserted-by":"crossref","first-page":"7519","DOI":"10.1200\/JCO.2022.40.16_suppl.7519","article-title":"Fixed-duration (FD) ibrutinib (I) + venetoclax (V) for first-line (1L) treatment (tx) of chronic lymphocytic leukemia (CLL)\/small lymphocytic lymphoma (SLL): three-year follow-up from the FD cohort of the phase 2 CAPTIVATE study","volume":"40","author":"Wierda","year":"2022","journal-title":"J Clin Oncol"},{"issue":"7","key":"2023120815065654000_hem2023000506C13","article-title":"M.D. fixed-duration ibrutinib-venetoclax in patients with chronic lymphocytic leukemia and comorbidities","volume":"1","author":"Kater","year":"2022","journal-title":"N Engl J Med Evid"},{"issue":"5","key":"2023120815065654000_hem2023000506C14","doi-asserted-by":"crossref","first-page":"874","DOI":"10.3324\/haematol.2017.182907","article-title":"Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis","volume":"103","author":"Mato","year":"2018","journal-title":"Haematologica"},{"issue":"31","key":"2023120815065654000_hem2023000506C15","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.1200\/JCO.21.01210","article-title":"Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia: results of the first randomized phase III trial","volume":"39","author":"Byrd","year":"2021","journal-title":"J Clin Oncol"},{"issue":"4","key":"2023120815065654000_hem2023000506C16","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1056\/NEJMoa2211582","article-title":"Zanubrutinib or ibrutinib in relapsed or refractory chronic lymphocytic leukemia","volume":"388","author":"Brown","year":"2023","journal-title":"N Engl J Med"},{"issue":"18","key":"2023120815065654000_hem2023000506C17","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.1182\/blood-2016-10-742437","article-title":"Ventricular arrhythmias and sudden death in patients taking ibrutinib","volume":"129","author":"Lampson","year":"2017","journal-title":"Blood"},{"issue":"suppl 1","key":"2023120815065654000_hem2023000506C18","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1182\/blood-2021-144336","article-title":"Zanubrutinib in combination with venetoclax for patients with treatment-na\u00efve (TN) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) with del(17p): early results from arm D of the SEQUOIA (BGB-3111-304) trial","volume":"138","author":"Tedeschi","year":"2021","journal-title":"Blood"},{"issue":"suppl 1","key":"2023120815065654000_hem2023000506C19","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1182\/blood-2022-168003","article-title":"Updated results from a multicenter, phase 2 study of acalabrutinib, venetoclax, obinutuzumab (AVO) in a population of previously untreated patients with CLL enriched for high-risk disease","volume":"140","author":"Ryan","year":"2022","journal-title":"Blood"},{"issue":"12","key":"2023120815065654000_hem2023000506C20","doi-asserted-by":"crossref","first-page":"e879","DOI":"10.1016\/S2352-3026(21)00307-0","article-title":"Zanubrutinib, obinutuzumab, and venetoclax with minimal residual disease-driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: a multicentre, single-arm, phase 2 trial","volume":"8","author":"Soumerai","year":"2021","journal-title":"Lancet Haematol"},{"issue":"4","key":"2023120815065654000_hem2023000506C21","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1111\/bjh.17984","article-title":"Long-term efficacy of first-line ibrutinib treatment for chronic lymphocytic leukaemia in patients with TP53 aberrations: a pooled analysis from four clinical trials","volume":"196","author":"Allan","year":"2022","journal-title":"Br J Haematol"},{"issue":"S3","key":"2023120815065654000_hem2023000506C22","doi-asserted-by":"crossref","DOI":"10.1097\/01.HS9.0000969460.15364.af","article-title":"P639: Zanubrutinib (ZANU) vs Bendamustine + Rituximab (BR) in patients (pts) with treatment-na\u00efve chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL): extended follow-up of the SEQUOIA study","volume":"7","author":"Munir","year":"2023","journal-title":"HemaSphere"},{"issue":"20","key":"2023120815065654000_hem2023000506C23","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1182\/blood.2022016953","article-title":"Ventricular arrhythmias and sudden death events following acalabrutinib initiation","volume":"140","author":"Bhat","year":"2022","journal-title":"Blood"},{"key":"2023120815065654000_hem2023000506C24","article-title":"Diminished humoral and cellular responses to SARS-CoV-2 vaccines in patients with chronic lymphocytic leukemia","volume-title":"Blood Adv","author":"Ujjani","year":"2022"},{"issue":"3","key":"2023120815065654000_hem2023000506C25","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1111\/bjh.18088","article-title":"The impact of B-cell-directed therapy on SARS-CoV-2 vaccine efficacy in chronic lymphocytic leukaemia","volume":"197","author":"Ujjani","year":"2022","journal-title":"Br J Haematol"},{"issue":"15","key":"2023120815065654000_hem2023000506C26","doi-asserted-by":"crossref","first-page":"4553","DOI":"10.1182\/bloodadvances.2022007812","article-title":"Venetoclax retreatment of patients with chronic lymphocytic leukemia after a previous venetoclax- based regimen","volume":"6","author":"Thompson","year":"2022","journal-title":"Blood Adv"},{"issue":"8","key":"2023120815065654000_hem2023000506C27","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/S1470-2045(22)00293-5","article-title":"Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial","volume":"23","author":"Tam","year":"2022","journal-title":"Lancet Oncol"},{"issue":"16, suppl","key":"2023120815065654000_hem2023000506C28","doi-asserted-by":"crossref","first-page":"7540","DOI":"10.1200\/JCO.2022.40.16_suppl.7540","article-title":"Four-year follow-up from a phase 2 study of obinutuzumab, ibrutinib, and venetoclax in CLL","volume":"40","author":"Rogers","year":"2022","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"2023120815065654000_hem2023000506C29","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1182\/blood-2020-136317","article-title":"Acalabrutinib in combination with venetoclax and obinutuzumab or rituximab in patients with treatment- na\u00efve or relapsed\/refractory chronic lymphocytic leukemia","volume":"136","author":"Woyach","year":"2020","journal-title":"Blood"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2023\/1\/421\/2175719\/421ujjani.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2023\/1\/421\/2175719\/421ujjani.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,8]],"date-time":"2023-12-08T15:11:34Z","timestamp":1702048294000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2023\/1\/421\/506469\/Dual-targeted-regimens-for-the-frontline-treatment"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,8]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12,8]]},"published-print":{"date-parts":[[2023,12,8]]}},"URL":"https:\/\/doi.org\/10.1182\/hematology.2023000506","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,12,8]]},"published":{"date-parts":[[2023,12,8]]}}}